【レポートの概要（一部）】
1. Report Overview
1.1 Next-Generation Antibody Therapies Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why you Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 Antibodies: An Overview
2.1.1 Monoclonal versus Polyclonal Antibodies
2.1.2 A Brief History of Antibody Drug Development
2.1.3 The Antibody Manufacturing Process
2.1.4 Trends in Antibody Development
2.2 Defining Next-Generation Antibodies
2.3 Classification of Next-Generation Antibody Therapies
2.4 The Need for Next-Generation Technologies
2.5 Development Trends for Next-Generation Antibodies
2.6 Scope of this Report
2.7 Phases of Clinical Trials
3. Next-Generation Antibody Therapies: World Market 2016-2026
3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2015
3.2 Leading Next-Generation Antibody Therapies
3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2026
3.4 How Will Segmental Market Shares Change to 2026?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2026
4. Leading Regional Markets 2016-2026
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2015
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2026
4.3 How Will Regional Market Shares Change to 2026?
4.4 US Next-Generation Antibody Therapies Market 2015-2026
4.5 EU5 Next-Generation Antibody Therapies Market 2016-2026
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2016-2026
4.7 Latin American Next-Generation Antibody Therapies Market 2016-2026
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2026
5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2026
5.1 Market Overview, 2016
5.2 Leading ADCs in 2016
5.3 Antibody-Drug Conjugates: Market Forecast 2016-2026
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2026
5.4.1 Competition for Leading Drugs Will Restrain Growth
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
5.5.1 Adcetris: Sales 2011-2015
5.5.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.5.4 Adcetris Sales Forecast 2016-2026
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Mixed Results from Different Clinical Trials
5.6.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
5.6.3 Kadcyla Sales Forecast 2016-2026
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounted for Over 50% of the Pipeline in 2015
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Have Attracted High-Value Deals and will Continue to do so
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2026
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.1.1 Granted Breakthrough Therapy Designation
5.11.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles
6. Engineered Antibodies: Market Forecast and Pipeline 2016-2026
6.1 Defining an ‘Engineered Antibody’
6.2 Market Overview 2016, and the Leading Engineered Antibodies
6.3 Leading Engineered Antibodies: Market Forecast 2016-2026
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2026
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo Sales Forecast 2016-2026
6.6 Gazyva / Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva Receives Second Approval
6.6.4 Gazyva Sales Forecast 2016-2026
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2016-2026
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune / Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2026
7.1 Bispecific Antibodies: Market Overview, 2016
7.2 Bispecific Antibodies: Market Forecast 2016-2026
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2016-2026
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2016-2026
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
7.5.2 Blincyto: Sales Forecast 2016-2026
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2016-2026
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2026
7.7.1 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.7.2 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.7.3 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.7.4 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.7.5 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.7.6 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.7.7 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.8 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline
8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2026
8.1 Antibody Fragments and ALPs: Market Overview, 2016
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2026
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2026
8.4 Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
8.4.1 Kalbitor: Sales Forecast 2016-2026
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2016-2026?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2016-2026
8.6.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7 Antibody Fragments and ALPs: Phase 3 Pipeline
8.7.1 Caplacizumab (anti-vWF, Ablynx)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.8 Antibody Fragments and ALPs: Phase 2 Pipeline
8.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.8.2 Ozoralizumab (anti-TNFα, Ablynx )
8.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.8.4 ESBA1008 (anti-VEGF, Novartis)
8.9 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9.1 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.9.2 ALX-0171 (anti-respiratory syncytial virus)
8.9.3 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.9.4 Other Phase 1 Candidates, and the Preclinical Pipeline
9. Biosimilar Antibodies: Market Forecast 2016-2026
9.1 Biosimilar Antibodies: Market Overview, 2016
9.2 Leading Biosimilar Antibodies in 2016.
9.3 Biosimilar Antibodies: Market Forecast 2016-2026
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2016-2026
9.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
9.4.2 Rising Incidence of Cancer will Drive Demand
9.4.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
9.4.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2026
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths: The Path Towards Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2016-2026
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia
11. Research Interviews
11.1 Interview with Dr Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, arGEN-X, the Netherlands and Belgium
11.2.1 arGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 arGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for arGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2026
12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2026
12.2 Current Status of the Market and Leading Segments
12.3 Leading Next-Generation Antibody Therapies Profiled in this Report
12.4 Leading Regional Markets
12.5 Development of the Market to 2026
12.6 Technology Platforms Will Continue to Attract Big Pharma Interest
12.7 Most Developers Continue to Target Cancer
12.8 Strategies for Growth in 2016-2026
【レポート販売概要】
■ タイトル：次世代抗体治療の世界市場予測2016-2026■ 英文：Next-Generation Antibody Therapies Market Forecast 2016-2026
■ 発行日：2016年4月
■ 調査会社：visiongain
■ 商品コード：VGAIN60630
■ 調査対象地域：グローバル
- 医療レポート：Dermatophytic Onychomycosis-疫学予測（～2022）EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022 Summary Dermatophytic onychomycosis (DO) is an infection of the nail fold or nail plate with dermatophytes, a type of fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton flocossom (Sterry et al., 2006). DO begins as a white/yellow spot under the tip of the nail. As the infection spreads …
- 架空ケーブルの世界市場2017-2021ABSTRACTAbout Overhead Cables Cables are a collection of electrical conductors that are insulated. These are used for transmission and distribution purposes. Overhead cables are installed above buildings and between electric poles. There is a presumption that underground cables are more reliable as they are less prone to damage from storms, lightning, and other disruptions. However, underground ca …
- モバイル衛星通信サービスの世界市場：ビデオサービス、音声サービス、データサービス、追跡及びモニタリングサービスSatellite communication is moving rapidly with the evolution of applications and mobile services. Mobile Satellite Service (MSS) offers enhanced voice and data quality to mobile users situated in remote locations. This technology is a type of data and voice transmission that occurs through satellite systems that can be accessed through land mobile, maritime, and aeronautical. The emerging advancem …
- 使い捨てリード線の世界市場規模及び予測：材料別（TPE、TPU、シリコン、PVC）、機械別（3リード、5リード、12リード、6リード）、エンドユーザー別（病院、診療所、長期ケア施設）、動向分析 2014-2025The global disposable lead wires market is expected to reach USD 999.4 million by 2025, according to a new study by Grand View Research, Inc. Rising incidence of hospital-acquired infections (HAIs) is the key driving factor for the market growth. The reusable lead wires are the major cause of the hospital-acquired bloodstream infections. Use of disposable lead wires eliminates the risk of cross-co …
- 神経変調療法用装置の世界市場：脳深部刺激療法、脊髄刺激療法、経頭蓋磁気刺激法Over the years, the global healthcare industry has witnessed a paradigm shift, and is now increasingly focused on minimally invasive therapies that not only treats a wide range of chronic and refractory disorders but also have fewer side effects. The demand for neuromodulation has increased significantly, because of patients’ preference for minimally invasive surgeries. Moreover, these therapies a …
- 赤外線検出器の世界市場：熱型/焦電型/マイクロボロメータ/InGaAs/MCT赤外線検出器About Infrared Detector An infrared detector is a device used to detect infrared radiation reflected or emitted by an object. Infrared detectors are widely adopted across several applications such as security, home automation, temperature sensors, appliances, gas and fire detection, and others. Infrared detectors, such as cooled and uncooled detectors, are extensively used in the Residential, Comm …
- カロテノイドの世界市場：βカロテン、ルテイン、ゼアキサンチン、アスタキサンチンAbout Carotenoids Carotenoids are a class of phytonutrients found in the cells of a wide variety of plants, bacteria, and algae, which help plants absorb light energy for the process of photosynthesis. They play an important antioxidant function of deactivating free radicals (single oxygen atoms that can damage cells by reacting with other molecules). Carotenoids are responsible for the bright red …
- ITセキュリティ投資の世界市場：ITセキュリティ製品、ITセキュリティサービスAbout IT Security IT security is used to protect data and information of single-user or multi-user networks. It protects data and information from unauthorized access and modification. IT security refers to measures taken to detect, monitor, report, and counter such threats. IT security spending refers to the expense incurred by enterprises and government organizations to secure their data, system …
- Laredo Petroleum Holdings, Inc.：石油・ガスバリューチェーン分析レポート2013Laredo Petroleum Holdings, Inc. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Laredo Petroleum Holdings, Inc." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Laredo Petroleum Holdings, Inc.”. The report provides key information relating to oil and gas assets of the company along with its operations across …
- ヨーロッパのEthylene-vinyl Acetate Copolymers市場The report provides a complete overview of the ethylene-vinyl acetate copolymers market in EU countries in a comprehensive and easily accessed format. Market current state, historical figures and future development are in the report. Scope The report gives in-depth analysis of the European Union market for ethylene-vinyl acetate copolymers with data for EU in total and by country Current statistic …
- MDM（モバイルデバイス管理）の世界市場2016-2020About MDM MDM is software that manages, secures, supports and monitors mobile devices, deployed across service providers, mobile operators, and across multiple mobile OS being used in enterprises. It allows distribution of applications, data and configuration settings for devices such as tablets, smartphones, mobile phones, and other mobile computing devices. Technavio’s analysts forecast the glob …
- 体外診断用医薬品（IVD）包装の世界市場2016-2020Technavios market research analyst predicts the global in-vitro diagnostics (IVD) packaging market to grow at a CAGR of around 3% between the period of 2016 and 2020. The prospects for growth in this market are driven by the recent increase in diagnostic services and a rise in the incidence and prevalence of chronic diseases and infections. Additionally, the growing practice of self-testing by pat …
- 球様細胞白質萎縮症(クラッベ病)治療のグローバル臨床試験動向（2014年H1）Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H1, 2014" provides data on the Globoid Cell Leukodystrophy (Krabbe Disease) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Globoi …
- 水浄化剤の世界市場2019-2023118 pages, November 2018 About this market Aluminum sulfate is one of the commonly used coagulants in the water clarifiers market. The elevated price conspiracy for aluminate sulfate for water and wastewater treatment applications is expected to impede the growth of water clarifiers during the forecast period. The major vendors are down with the allegations for rig bids and artificially elevated p …
- NTPC Limited：発電所及びSWOT分析2013NTPC Limited - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summarized and detail …
